Shares of Lantheus Holdings LNTH fell in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 79.41% year over year to $0.07, which beat the estimate of $0.01.
Revenue of $94,152,000 up by 5.38% year over year, which beat the estimate of $92,230,000.
Guidance
The upcoming fiscal year's EPS expected to be between $0.34 and $0.39.
The upcoming fiscal year's revenue expected to be between $385,000,000 and $400,000,000.
Details Of The Call
Date: Feb 25, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/fnf394tc
Recent Stock Performance
Company's 52-week high was at $20.29
52-week low: $8.67
Price action over last quarter: Up 69.92%
Company Profile
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
